Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Evidence: Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379

Computable Name:

version: 9; Last updated: 2025-12-11 20:35:21+0000; Language: en

Profile: NonComparativeEvidence

url: https://fevir.net/resources/Evidence/267234

identifier: FEvIR Object Identifier/267234, FEvIR Linking Identifier/NCT03421379-secondaryOutcomeMeasure-0--OG000

name: NCT03421379_secondaryOutcomeMeasure_0_OG000

title: Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379

citeAs:

Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267234. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267234. Computable resource at: https://fevir.net/resources/Evidence/267234#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Glucagon Nasal Powder

note: ,

Outcome Measure Population Description: All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data.

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: A single dose of 3 mg glucagon nasal powder was administered intranasally (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)

variableDefinition

variableRole: Outcome

observed: Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration - (NCT03421379)

statistic

statisticType: geometric mean

quantity: 113 milligram/deciliter (mg/dL)

SampleSizes

-KnownDataCount
*71

AttributeEstimates

-TypeQuantity
*Geometric Coefficient of Variation32 milligram/deciliter (mg/dL)